New Approved Malaria Vaccine: Ghana is the First Country to Approve the Malaria Vaccine.
New Approved Malaria Vaccine: Over the years children die of Malaria and efforts are being made to prevent the illness like other childhood diseases.
The good news is here as a vaccine has been manufactured and approved by WHO.
New Approved Malaria Vaccine: In Ghana, an Oxford University malaria vaccine has been approved for use. The African country is stepping up its efforts to tackle the mosquito-borne disease that claims the life of a child every minute.
New Approved Malaria Vaccine: The use of a malaria vaccine produced by Britain’s Oxford University has been approved in Ghana. It is the first time the vaccine has been approved by a regulatory body anywhere in the globe.
“The vaccine has been authorized for use in children aged 5-36 months, the age group most at risk of malaria mortality,” the university stated in a statement.
“It is envisaged that this initial critical stage will enable the vaccine to successfully prevent malaria in Ghanaian and African youngsters,” it continued.
It marked the “culmination of 30 years of malaria vaccine research at Oxford with the design and provision of a high efficacy vaccine that can be supplied at adequate scale to the countries who need it most,” according to Professor Adrian Hill, the program’s chief investigator and director of the university’s Jenner Institute.
New Approved Malaria Vaccine
The initiative is one of many aimed at combating the illness that claims more than 600,000 lives annually, the majority of them infants in Africa. The development of vaccines has long been hampered by the malaria parasite’s complex structure and life cycle.
The first malaria vaccine, Mosquirix from British pharmaceutical company GSK, was approved by the World Health Organization last year after decades of development (WHO). But, the company’s ability to generate enough dosages has been hindered by a lack of capital and economic potential.
More than a million kids in Africa have received the GSK vaccination thus far. According to research, its efficiency is around 60%, however over time, that protection drastically decreases.
Due to an agreement to produce up to 200 million doses yearly with the Serum Institute of India, the Oxford vaccine offers a manufacturing advantage.
In contrast, GSK has committed to generating no more than 15 million doses of Mosquirix annually through 2028, which is far less than the estimated 100 million doses annually of the four-dose vaccine that the WHO estimates is required in the long run to protect about 25 million children.
Vaccine Efficacy: 80% of the time, effectiveness
A medical journal released mid-stage results from the Oxford vaccination experiment involving more than 400 young infants in September.
At 12 months after the fourth dose, vaccine efficacy was 70% in the group that received a lower dose of the immune-stimulating adjuvant and 80% in the higher dose group. Before Burkina Faso’s malaria season’s peak, the doses were given out.
A medical journal is anticipated to publish the results of phase III clinical trial that is currently taking place in Burkina Faso, Kenya, Mali, and Tanzania and has enrolled 4,800 children.